Table 2.

Associations between pharmaceutically treated anxiety and depression with incident CVD risk after breast cancer diagnosis

	Age-adjusted model	Partially adjusted model	Fully adjusted model
	HR (95% CI)	HR (95% CI)	HR (95% CI)
Psychological factors
Anxiety	1.60 (1.13–2.25)*	1.47 (1.04–2.07)*	1.48 (1.05–2.08)*
Depression	0.91 (0.53–1.57)	0.90 (0.53–1.55)	0.89 (0.52–1.53)
Demographics
Age (continuous)	1.07 (1.06–1.08)*	1.06 (1.05–1.08)*	1.06 (1.05–1.08)*
Traditional CVD risk factors
Hypertension	–	1.77 (1.29–2.42)*	1.80 (1.32–2.46)*
Hypercholesterolemia	–	1.77 (1.29–2.42)*	1.63 (1.15–2.33)*
Diabetes mellitus	–	1.02 (0.63–1.64)	1.05 (0.65–1.69)
Clinical characteristics
Tumor stage
Stage I (reference)	–	–	–
Stage II	–	–	1.14 (0.81–1.61)
Stage III	–	–	0.97 (0.52–1.80)
Stage IV	–	–	0.93 (0.29–3.05)
Cancer treatment
Chemotherapy	–	–	1.05 (0.65–1.69)
Radiation	–	–	0.78 (0.57–1.06)
Hormone treatment	–	–	0.59 (0.42–0.83)*

Information is provided in hazard ratios (HR) with 95% confidence intervals (95% CI). Partially adjusted = adjusted for age and the traditional cardiovascular risk factors (i.e., hypertension, hypercholesterolemia, and diabetes mellitus) present in the 12 months prior to cancer diagnosis; fully adjusted = adjusted for traditional cardiovascular risk factors and clinical information (tumor stage and treatment information, that is chemotherapy, radiation, and hormone treatment). Psychological and traditional CVD risk factors = being pharmaceutically treated in the 12 months prior to breast cancer diagnosis. *p < 0.05